



(19)

(11) Publication number: **2000128768**

Generated Document.

PATENT ABSTRACTS OF JAPAN(21) Application number: **10296774**(51) Intl. Cl.: **A61K 7/50 A61K 7/48**(22) Application date: **19.10.98**

(30) Priority:

(43) Date of application publication: **09.05.00**

(84) Designated contracting states:

(71) Applicant: **SHISEIDO CO LTD**(72) Inventor: **KOGA NOBUYOSHI**

(74) Representative:

(54) BODY RINSE**(57) Abstract:**

PROBLEM TO BE SOLVED: To provide a body rinse that gives the body a proper amount of oil components after bathing and shows excellent usability.

SOLUTION: This body rinse comprises an oil-in-water emulsion composition having the size of the emulsified oil particles of ≤ 10 microns and the whole oil content of ≥ 51 wt.% based on the whole body rinse and contains a nonvolatile polysiloxane or a volatile oil component in an amount of ≥ 2 wt.% based on the whole oil components.

COPYRIGHT: (C)2000,JPO

BEST AVAILABLE COPY



(19)

Generated Document.

(11) Publication number: 2000178125

PATENT ABSTRACTS OF JAPAN

(21) Application number: 10361637

(51) Int'l. Cl.: A61K 7/00 A61K 7/06 A61K 7/42 A61K 7/48

(22) Application date: 18.12.98

(30) Priority:

(43) Date of application publication: 27.06.00

(84) Designated contracting states:

(71) Applicant: KAO CORP

(72) Inventor: HASEGAWA HIROYUKI
WATANABE TAICHI
FUKUHARA KAZUHISA
HORIZUMI TERUO
NISHISAKA TAKAHIRO
YAMAZAKI SEIJI

(74) Representative:

(54) COSMETICS FOR SKIN

(57) Abstract:

PROBLEM TO BE SOLVED: To provide cosmetics for the skin excellent in feeling from applying to after drying, high in permeability of a water-soluble pharmacological component to skin and sustained efficacy.

SOLUTION: The cosmetics for skin include (A) a copolymer having cationic group and crosslinked structure and satisfies $0.3 \leq \eta_1 \leq 20$ (Pa.sec), $0.01 \leq \eta_2 \leq 5$ (Pa.sec), and $\eta_1 > \eta_2$ where η_1 is the viscosity of 0.5% hydrogel at 25°C under 1 sec⁻¹ of the shearing rate, η_2 is the viscosity under 10 sec⁻¹ of the shearing rate, and (B) the aqueous pharmacological component.

COPYRIGHT: (C)2000,JPO